Kennedy Proposes Restricting Antidepressants, Makes Unfounded Comparison to Heroin

In a move that has sparked immediate pushback from mental health professionals, Health Secretary Robert F. Kennedy Jr. announced new federal initiatives Monday aimed at restricting antidepressant prescribing practices across the country. The announcement came during a brief appearance at a Make America Healthy Again Institute event focused on what organizers termed “overmedicalization” in American healthcare.

The initiatives specifically target selective serotonin reuptake inhibitors (SSRIs), a class of medications that includes widely prescribed drugs such as Prozac, Zoloft, Lexapro, and Paxil. These medications are standard treatments for depression, anxiety, post-traumatic stress disorder, and various other mental health conditions affecting millions of Americans.

Participants at the event claimed, without presenting scientific evidence, that SSRIs are overprescribed to Americans, particularly young people. They argued that patients receive these medications without proper informed consent, that the drugs are harmful, and that discontinuation can be problematic.

Mental health experts have quickly mobilized to counter Kennedy’s claims. This represents the latest chapter in an ongoing conflict between the Health Secretary and the medical establishment over mental health treatment approaches.

Kennedy has a documented history of making controversial statements about antidepressants and other psychiatric medications. He has repeatedly suggested, contrary to scientific consensus, that SSRIs contribute to violent behavior and has even linked them to mass shootings, including those at schools.

In a particularly contentious statement from a podcast appearance last year, Kennedy claimed that “every Black kid is now just standard put on Adderall, SSRIs, benzos, which are known to induce violence.” This statement has been widely condemned by both mental health and civil rights organizations as both factually incorrect and racially insensitive. Kennedy’s suggested alternative—that Black children should be “reparented” and work on farms—has drawn additional criticism.

The Health Secretary has also frequently claimed that discontinuing antidepressants is extremely difficult, even suggesting they are “harder to quit than heroin.” This assertion was notably repeated during his confirmation hearing in January 2025. However, addiction specialists have firmly rejected this comparison.

Keith Humphreys, a prominent addiction researcher at Stanford University, told NPR that antidepressants and heroin “are in different universes when it comes to addiction risk.” Medical literature does not support Kennedy’s claim, and experts worry such statements may frighten patients away from potentially life-saving treatments.

The pharmaceutical industry has also responded to the announcement, with representatives arguing that these medications undergo rigorous clinical trials and FDA approval processes before reaching patients. Industry spokespersons point to decades of data showing these medications’ efficacy in treating depression and anxiety disorders.

The American Psychiatric Association released a statement expressing “deep concern” over the administration’s approach to mental health policy, noting that restricting access to psychiatric medications could have severe consequences for patients already struggling with mental illness.

Public health experts worry that Kennedy’s initiatives could exacerbate the ongoing mental health crisis in America. According to recent data from the National Institute of Mental Health, approximately 21 million adults in the United States experienced at least one major depressive episode in 2022, with depression remaining one of the leading causes of disability worldwide.

While discontinuation symptoms can occur when stopping antidepressants, medical professionals emphasize that these can typically be managed with proper medical supervision and gradual tapering of dosages. They stress that the potential benefits of these medications for those with moderate to severe depression often outweigh the risks.

As the administration moves forward with these initiatives, healthcare providers, patient advocacy groups, and medical associations are preparing to scrutinize the specific policy proposals and their potential impact on mental health treatment in America.